To access any content or REGISTER in less than 3 minutes.
Register
Menu
Are you medical worker?
No, visit
Your account was deleted
Please login to MyServier to continue reading this content
or sign in without a password
No account yet?
You already have an account associated with this email address. Please log in to continue.
or sign in without a password
No account yet?

What the data tell us about venetoclax activity specifically in IDH1 v/s IDH2 mutant AML?

03.09.2026
3

IVO Bridge – Episode 3
In this video, Dr. Eytan Stein presents the mechanism of ivosidenib in reversing myeloid differentiation blocks and the comparative survival outcomes of venetoclax and azacitidine in patients with IDH1 versus IDH2 mutant AML.

Dr. Eytan Stein – Hematologist – Oncologist – Memorial Sloan Kettering Cancer Center, New York, USA

Content exclusive for connected users. Please sign in or register to access more.

Already have an account?

New here?

Create account